Home time among older adults with acute myeloid leukemia by therapy intensity

Authors

Christopher E. Jensen,[1,2] Allison M. Deal,[3] Alexis C. Wardell,[3] Hillary M. Heiling,[2,3] Konan E. Beke[1] and Daniel R. Richardson[1,3]

[1]University of North Carolina School of Medicine; [2]University of North Carolina Gillings School of Global Public Health and [3]Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA

Correspondence:
C.E. JENSEN - christopher.jensen@unchealth.unc.edu

Table S1. Proportion of person-days spent at home by month from diagnosis among older adults with AML, stratified by first-line therapy

Month	N	Full Cohort (n=197) Mean PDH (95% CI)	N	HMA Monotherapy (n=64) Mean (95% CI)	N	HMA+VEN (n=58) Mean (95% CI)	N	Anthracycline-Containing Regimen (n=75) Mean (95% CI)
1	186	0.34 (0.30-0.37)	56	0.45 (0.39-0.51)	56	0.47 (0.42-0.53)	74	0.15 (0.10-0.19)
2	160	0.47 (0.43-0.51)	45	0.57 (0.50-0.64)	47	0.57 (0.52-0.63)	68	0.33 (0.27-0.38)
3	143	0.62 (0.58-0.66)	40	0.65 (0.58-0.73)	38	0.68 (0.60-0.76)	65	0.57 (0.52-0.62)
4	131	0.65 (0.61-0.69)	36	0.68 (0.60-0.75)	33	0.71 (0.62-0.79)	62	0.61 (0.56-0.66)
5	124	0.68 (0.63-0.72)	33	0.76 (0.70-0.81)	30	0.75 (0.67-0.82)	61	0.60 (0.53-0.66)
6	119	0.71 (0.67-0.75)	33	0.76 (0.71-0.81)	28	0.79 (0.71-0.86)	58	0.65 (0.58-0.71)
7	113	0.72 (0.67-0.76)	31	0.80 (0.75-0.85)	27	0.77 (0.69-0.85)	55	0.65 (0.57-0.73)
8	99	0.72 (0.67-0.77)	26	0.70 (0.63-0.78)	25	0.80 (0.71-0.90)	48	0.69 (0.61-0.77)
9	89	0.77 (0.73-0.81)	24	0.77 (0.71-0.82)	20	0.80 (0.72-0.88)	45	0.76 (0.69-0.83)
10	82	0.82 (0.78-0.85)	24	0.79 (0.72-0.85)	18	0.85 (0.78-0.91)	40	0.83 (0.77-0.88)
11	76	0.80 (0.76-0.85)	22	0.76 (0.66-0.85)	15	0.82 (0.72-0.91)	39	0.82 (0.76-0.88)
12	72	0.80 (0.75-0.85)	21	0.78 (0.69-0.86)	13	0.83 (0.74-0.93)	38	0.80 (0.72-0.88)

AML: Acute myeloid leukemia, HMA: Hypomethylating agent, VEN: Venetoclax, PDH: Proportion of days at home, CI: Confidence interval. Number of subjects (N) reflects number of individuals in each group surviving at the end of the respective month. PDH for each month was calculated as the proportion of person-days not engaged in oncologic care among these survivors.